Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Iovance Biotherapeutics (IOVA) over the last 12 years, with Q3 2025 value amounting to -$89.5 million.

  • Iovance Biotherapeutics' Free Cash Flow fell 4617.13% to -$89.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$351.8 million, marking a year-over-year increase of 594.39%. This contributed to the annual value of -$364.1 million for FY2024, which is 521.75% up from last year.
  • Iovance Biotherapeutics' Free Cash Flow amounted to -$89.5 million in Q3 2025, which was down 4617.13% from -$74.9 million recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Free Cash Flow high stood at -$61.3 million for Q3 2024, and its period low was -$126.4 million during Q1 2024.
  • For the 3-year period, Iovance Biotherapeutics' Free Cash Flow averaged around -$93.0 million, with its median value being -$89.5 million (2025).
  • Its Free Cash Flow has fluctuated over the past 5 years, first surged by 3011.52% in 2024, then tumbled by 4617.13% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Free Cash Flow (Quarter) stood at -$87.5 million in 2023, then rose by 11.44% to -$77.5 million in 2024, then fell by 15.56% to -$89.5 million in 2025.
  • Its Free Cash Flow was -$89.5 million in Q3 2025, compared to -$74.9 million in Q2 2025 and -$109.9 million in Q1 2025.